These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 8105596)

  • 61. Pros and cons of 5-HT
    Rahimian R; Fakhfouri G; Zirak MR
    Biomed Pharmacother; 2019 Oct; 118():109301. PubMed ID: 31402188
    [No Abstract]   [Full Text] [Related]  

  • 62. Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.
    Adell A
    IDrugs; 2010 Dec; 13(12):900-10. PubMed ID: 21154150
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of 5-HT5A antagonists in animal models of schizophrenia, anxiety and depression.
    Kassai F; Schlumberger C; Kedves R; Pietraszek M; Jatzke C; Lendvai B; Gyertyán I; Danysz W
    Behav Pharmacol; 2012 Aug; 23(4):397-406. PubMed ID: 22785385
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The enantiomers of zacopride: an intra-species comparison of their potencies in functional and anxiolytic models.
    Bill DJ; Coleman J; Hallett I; Middlefell VC; Rhodes KF; Fletcher A
    Br J Pharmacol; 1995 Jul; 115(5):775-80. PubMed ID: 8548176
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Current status of the activity of 5-HT3 receptor antagonists in animal pharmacology].
    Raynaud G
    Ann Pharm Fr; 1995; 53(1):19-23. PubMed ID: 7741422
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [An outline of 5-HT3 receptor antagonists (1)--In pharmacological actions].
    Tsukagoshi S; Ohta J; Taguchi T
    Gan To Kagaku Ryoho; 1993 Nov; 20(14):2108-14. PubMed ID: 8239673
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Psychiatric Drug Discovery and Development--SRI's Third Annual Conference.
    Curry K
    IDrugs; 2005 Jun; 8(6):475-8. PubMed ID: 15906192
    [No Abstract]   [Full Text] [Related]  

  • 68. Behavioural pharmacology of 5-HT3 receptor ligands.
    Barnes JM; Barnes NM; Cooper SJ
    Neurosci Biobehav Rev; 1992; 16(1):107-13. PubMed ID: 1553101
    [TBL] [Abstract][Full Text] [Related]  

  • 69. British Association for Psychopharmacology--2008 Summer Meeting.
    Jenkins TA
    IDrugs; 2008 Oct; 11(10):720-3. PubMed ID: 18828070
    [No Abstract]   [Full Text] [Related]  

  • 70. Droperidol and 5-HT3-receptor antagonists, alone or in combination, for prophylaxis of postoperative nausea and vomiting. A meta-analysis of randomised controlled trials.
    Eberhart LH; Morin AM; Bothner U; Georgieff M
    Acta Anaesthesiol Scand; 2000 Nov; 44(10):1252-7. PubMed ID: 11065206
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The role of serotonin in antipsychotic drug action.
    Meltzer HY
    Neuropsychopharmacology; 1999 Aug; 21(2 Suppl):106S-115S. PubMed ID: 10432496
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Volunteer models for predicting antiemetic activity of 5-HT3-receptor antagonists.
    Minton NA
    Br J Clin Pharmacol; 1994 Jun; 37(6):525-30. PubMed ID: 7917768
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
    De Ponti F; Tonini M
    Drugs; 2001; 61(3):317-32. PubMed ID: 11293643
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Physiology and pathophysiology of the 5-HT3 receptor.
    Färber L; Haus U; Späth M; Drechsler S
    Scand J Rheumatol Suppl; 2004; 119():2-8. PubMed ID: 15515404
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Review: 5-HT1, 5-HT2, 5-HT3 and 5-HT7 Receptors and their Role in the Modulation of Pain Response in the Central Nervous System.
    Cortes-Altamirano JL; Olmos-Hernandez A; Jaime HB; Carrillo-Mora P; Bandala C; Reyes-Long S; Alfaro-Rodríguez A
    Curr Neuropharmacol; 2018 Jan; 16(2):210-221. PubMed ID: 28901281
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Ondansetron--the first highly selective 5-HT3 antagonist in therapy of psychiatric diseases].
    Broocks A
    Fortschr Neurol Psychiatr; 1992 Jun; 60(6):227-36. PubMed ID: 1386589
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The role of serotonin receptors in the action of atypical antipsychotic drugs.
    Meltzer HY; Massey BW
    Curr Opin Pharmacol; 2011 Feb; 11(1):59-67. PubMed ID: 21420906
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacologic modification of serotonergic function: drugs for the study and treatment of psychiatric and other disorders.
    Fuller RW
    J Clin Psychiatry; 1986 Apr; 47 Suppl():4-8. PubMed ID: 3514585
    [TBL] [Abstract][Full Text] [Related]  

  • 79. AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders.
    Ivachtchenko AV; Lavrovsky Y; Okun I
    J Alzheimers Dis; 2016 May; 53(2):583-620. PubMed ID: 27232215
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Risperdal: a new hope for schizophrenic patients?].
    Fortschr Neurol Psychiatr; 1994 May; 62(5 Suppl):1-4. PubMed ID: 9131061
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.